28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details

臨床試験数 : 261 / 薬物数 : 276 - (DrugBank : 81) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 178

11 trials found

diseases per page:

Showing 1 to 10 of 11 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00790647 (ClinicalTrials.gov)	June 2008	12/11/2008	Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidos ...	Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With ...	Multiple Myeloma	Biological: filgrastim;Drug: bortezomib;Drug: melphalan;Procedure: Stem Cell Infusion	Boston Medical Center	NULL	Completed	18 Years	65 Years	All	10	Phase 2	United States
2	NCT01998503 (ClinicalTrials.gov)	December 2007	15/11/2013	Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL ...	Induction Therapy With Bortezomib and Dexamethasone Followed by Autologous Stem Cell Transplantation ...	Amyloidosis	Drug: Bortezomib;Drug: dexamethasone;Biological: filgrastim;Procedure: autologous hematopoietic stem ...	Nanjing University School of Medicine	NULL	Completed	18 Years	65 Years	Both	56	Phase 3	China
3	EUCTR2006-006395-37-GB (EUCTR)	06/09/2007	31/07/2007	A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients w ...	A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients w ...	The medical condition to be investigated is systemic AL Amyloidosis, a disorder of protein folding i ...	Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Product Name: Cyclophosphamide INN ...	Joint UCLH and UCL Biomedical Research Unit	NULL	Not Recruiting			Female: yes Male: yes	48	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United Kingdom
4	NCT00477971 (ClinicalTrials.gov)	October 2005	23/5/2007	Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem C ...	Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone ...	Multiple Myeloma and Plasma Cell Neoplasm	Biological: filgrastim;Drug: dexamethasone;Drug: melphalan;Procedure: autologous hematopoietic stem ...	Mayo Clinic	National Cancer Institute (NCI)	Completed	18 Years	N/A	All	89	Phase 3	United States
5	NCT00064337 (ClinicalTrials.gov)	January 2004	8/7/2003	S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients ...	S0115, A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m) And Autologous Peripheral ...	Multiple Myeloma;Plasma Cell Myeloma	Biological: filgrastim;Drug: cyclophosphamide;Drug: dexamethasone;Drug: melphalan;Drug: thalidomide; ...	Southwest Oncology Group	National Cancer Institute (NCI)	Completed	18 Years	120 Years	All	104	Phase 2	United States
6	NCT00052884 (ClinicalTrials.gov)	October 2003	24/1/2003	Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing P ...	A Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan With Stem Cell Reconstit ...	Drug/Agent Toxicity by Tissue/Organ;Multiple Myeloma and Plasma Cell Neoplasm	Biological: filgrastim;Drug: amifostine trihydrate;Drug: melphalan;Procedure: bone marrow ablation wi ...	Eastern Cooperative Oncology Group	National Cancer Institute (NCI)	Terminated	18 Years	70 Years	Both	8	Phase 1	United States
7	NCT00089167 (ClinicalTrials.gov)	May 2002	4/8/2004	Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untr ...	Risk Adapted Intravenous Melphalan and Adjuvant Thalidomide and Dexamethasone for Untreated Patients ...	Multiple Myeloma and Plasma Cell Neoplasm	Biological: filgrastim;Drug: dexamethasone;Drug: melphalan;Drug: thalidomide	Memorial Sloan Kettering Cancer Center.	National Cancer Institute (NCI)	Completed	18 Years	N/A	Both		Phase 2	United States
8	NCT00075608 (ClinicalTrials.gov)	August 2001	9/1/2004	2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis	Phase II Trial of Second Autologous Transplantation in AL Amyloidosis	Multiple Myeloma;Plasma Cell Neoplasm	Biological: filgrastim;Drug: melphalan;Procedure: autologous stem cell transplantation;Procedure: st ...	Boston Medical Center	NULL	Terminated	18 Years	65 Years	All	12	Phase 2	United States
9	NCT00075621 (ClinicalTrials.gov)	August 2000	9/1/2004	Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloido ...	A Phase II Trial of Tandem Transplantation in AL Amyloidosis	Multiple Myeloma	Drug: filgrastim;Drug: melphalan;Procedure: autologous peripheral blood stem cell transplantation	Boston Medical Center	NULL	Completed	18 Years	65 Years	All	62	Phase 2	United States
10	NCT00007995 (ClinicalTrials.gov)	July 1999	6/1/2001	Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or ...	Phase 2 Study Of High Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support In Pa ...	Multiple Myeloma and Plasma Cell Neoplasm	Biological: filgrastim;Biological: recombinant interferon alfa;Biological: sargramostim;Drug: busulf ...	Herbert Irving Comprehensive Cancer Center	National Cancer Institute (NCI)	Completed	18 Years	N/A	Both	75	Phase 2	United States

First Previous1 2Next Last